Last updated: September 25, 2026
M.V.I. Pediatric is a preservative-free, injectable multivitamin product for pediatric patients receiving parenteral nutrition. Its commercial value is driven less by patent exclusivity than by sterile manufacturing capability, vitamin stability, hospital supply reliability, and compatibility with neonatal and pediatric parenteral nutrition systems. The central excipient is polysorbate 80, which supports solubilization of fat-soluble vitamins in an aqueous injectable product. The main commercial opportunities are improved ready-to-use presentations, stronger supply continuity, tighter control of oxidation and particulate risk, and region-specific pediatric nutrition products.
What is M.V.I. Pediatric and how is it administered?
M.V.I. Pediatric is a multiple-vitamin injection supplied for intravenous administration after dilution and admixture into an appropriate parenteral nutrition solution. The product is used in pediatric patients when oral or enteral vitamin supplementation is impractical or inadequate.
The formulation contains water-soluble and fat-soluble vitamins, including vitamins A, D, E, and K, as well as B-complex vitamins, vitamin C, folic acid, biotin, and cyanocobalamin. The product is intended for use in neonates, infants, children, and adolescents under dosing instructions tied to body weight and clinical status.
Representative active composition
| Component |
Representative amount per 5 mL vial |
| Vitamin A |
Approximately 2,300 IU |
| Vitamin D3 |
Approximately 400 IU |
| Vitamin E |
Approximately 7 IU |
| Vitamin K1 |
Approximately 200 mcg |
| Ascorbic acid |
Approximately 80 mg |
| Thiamine |
Approximately 1.2 mg |
| Riboflavin |
Approximately 1.4 mg |
| Niacinamide |
Approximately 17 mg |
| Pyridoxine |
Approximately 1 mg |
| Folic acid |
Approximately 140 mcg |
| Dexpanthenol |
Approximately 5 mg |
| Biotin |
Approximately 20 mcg |
| Cyanocobalamin |
Approximately 1 mcg |
Exact strength, package configuration, and labeling should be confirmed against the current FDA-approved prescribing information and product carton. DailyMed identifies M.V.I. Pediatric as a sterile injectable multivitamin product intended for parenteral nutrition use.[1]
What excipients are used in M.V.I. Pediatric?
The principal inactive ingredients identified in public product information are polysorbate 80, hydrochloric acid, sodium hydroxide, and water for injection. Hydrochloric acid and sodium hydroxide are used for pH adjustment. The formulation is preservative-free.[1]
| Excipient |
Functional role |
Commercial and technical relevance |
| Polysorbate 80 |
Solubilizer and emulsifying aid for fat-soluble vitamins |
Controls aqueous dispersion but creates oxidation, peroxide, and degradation-control requirements |
| Hydrochloric acid |
pH adjustment |
Supports target pH and product stability |
| Sodium hydroxide |
pH adjustment |
Used to bring the formulation into its specified pH range |
| Water for injection |
Vehicle |
Requires sterile, low-endotoxin pharmaceutical water |
| No antimicrobial preservative |
Preservative-free sterile design |
Supports neonatal use but increases aseptic-processing and container-closure demands |
Polysorbate 80 is strategically important because vitamins A, D, E, and K have limited aqueous solubility. Removing the surfactant would require a different delivery system, such as a lipid emulsion, cyclodextrin complex, mixed micellar system, or another parenterally acceptable solubilization platform.
How does the excipient strategy support product performance?
The formulation uses a relatively simple excipient system, but the manufacturing burden is high. The principal risks are chemical degradation, physical instability, adsorption, particulate formation, and incompatibility with parenteral nutrition admixtures.
Solubilization of fat-soluble vitamins
Polysorbate 80 enables the inclusion of fat-soluble vitamins in an aqueous injectable product. It can improve dispersion and reduce visible separation. Its concentration must be controlled because excessive surfactant may increase toxicity, interact with infusion components, or alter the behavior of the admixture after dilution.
Oxidation and peroxide control
Polysorbate 80 can contain or generate peroxide species during storage. Peroxides may accelerate degradation of oxidation-sensitive vitamins, including vitamin A, vitamin C, and certain B vitamins. A competitive product therefore needs:
- Low-peroxide excipient specifications.
- Control of oxygen exposure during compounding and filling.
- Light-protective packaging.
- Validated headspace and container-closure controls.
- Stability data in the marketed vial and after dilution into parenteral nutrition solutions.
The excipient strategy is commercially defensible only when supported by degradation studies, impurity profiling, and in-use stability data.
Preservative-free design
A preservative-free formulation is aligned with neonatal and pediatric use. It avoids exposure to antimicrobial preservatives that may be unsuitable for premature infants or critically ill patients. The trade-off is a greater dependence on aseptic processing, single-dose packaging, validated sterilization controls, and container-closure integrity.
pH and compatibility
The product must be compatible with the final parenteral nutrition solution, including amino acids, dextrose, electrolytes, trace elements, and lipid emulsions. Compatibility can depend on pH, temperature, light exposure, concentration, and the order of admixture. A formulation that performs well in the vial may still generate precipitation, discoloration, potency loss, or adsorption after transfer into a nutrition bag.
What patents protect M.V.I. Pediatric?
M.V.I. Pediatric does not appear to depend on a meaningful active patent estate for its commercial position. Its primary barriers are regulatory approval, sterile injectable know-how, validated manufacturing, customer qualification, and supply-chain reliability.
The product is a conventional multivitamin injection rather than a biologic. Biosimilar provisions do not apply. Any intellectual-property value is more likely to arise from formulation improvements, packaging, manufacturing processes, or a redesigned delivery system than from the basic vitamin combination.
Patent categories with potential relevance
| Patent category |
Relevance to M.V.I. Pediatric |
| Core vitamin composition |
Likely limited patent value because the vitamins and general use are longstanding |
| Polysorbate-based solubilization |
Possible formulation claims, but freedom-to-operate depends on claim scope and prior art |
| Low-peroxide surfactant systems |
Potential improvement area |
| Vitamin-stabilizing combinations |
Possible claims around antioxidants, chelators, pH, oxygen control, or packaging |
| Ready-to-use presentations |
Potential claims covering containers, dilution, or infusion systems |
| Manufacturing methods |
Potential protection for sterile mixing, filtration, filling, and stability-control processes |
| Parenteral nutrition compatibility |
Potential method-of-use or admixture claims, subject to patentability |
| Packaging |
Possible claims for light protection, oxygen control, or dose-specific delivery |
A generic manufacturer should not assume that the absence of a basic composition patent eliminates all freedom-to-operate risk. Formulation and container patents can remain relevant even when the underlying drug product is old.
What is the Orange Book status of M.V.I. Pediatric?
M.V.I. Pediatric is not a biologic and does not require a biosimilar pathway. Any abbreviated approval strategy would generally be evaluated under the FDA’s ANDA framework if an appropriate reference-listed drug and product-specific requirements are available. A 505(b)(2) route could become relevant for a materially different formulation, presentation, excipient system, or clinical use.
The FDA Orange Book should be checked for:
- Reference-listed-drug designation.
- Approved strength and dosage form.
- Patent-listing status.
- Exclusivity codes.
- Therapeutic-equivalence evaluations.
- Withdrawal or discontinuation status.
Public product labeling establishes the clinical and formulation profile but does not by itself establish patent expiry or current listing status. The FDA Orange Book remains the controlling public source for product-specific patent and exclusivity information.[2]
When does M.V.I. Pediatric lose exclusivity?
M.V.I. Pediatric appears to be an established, mature injectable product rather than a recently launched product protected by new chemical entity exclusivity. The commercial risk is therefore unlikely to be a pending loss of five-year NCE exclusivity. Generic entry risk depends on the availability of a reference product, current manufacturing status, FDA approval requirements, and any listed formulation or method-of-use patents.
| Exclusivity issue |
Assessment |
| NCE exclusivity |
Not expected to be the primary commercial issue |
| Orphan-drug exclusivity |
Not applicable to the general pediatric multivitamin indication |
| Pediatric exclusivity |
No product-specific six-month pediatric extension should be assumed without an FDA record |
| Biologic exclusivity |
Not applicable |
| Formulation exclusivity |
Could arise only from a later approved formulation or delivery innovation |
| Patent-based exclusivity |
Requires current Orange Book and patent-record review |
| Regulatory exclusivity |
Could attach to a new formulation or new clinical indication |
Paragraph IV challenges would be relevant only if an ANDA applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed. For a mature injectable multivitamin product, the more likely entry pathway is a standard abbreviated application or a 505(b)(2) application rather than a litigation-driven challenge to a strong composition patent.
What formulation patents could protect a competing M.V.I. Pediatric product?
The strongest patent opportunities are likely to involve measurable performance improvements rather than the vitamin list itself.
Potentially protectable formulation concepts
-
Low-peroxide polysorbate 80 systems. Claims could address surfactant quality, peroxide thresholds, vitamin degradation rates, and storage conditions.
-
Alternative solubilizers. A competitor could pursue mixed micelles, poloxamers, cyclodextrins, or other injectable solubilization systems. The safety and regulatory burden would be substantial.
-
Enhanced light protection. Packaging and formulation claims could target reduced photodegradation of vitamin A, vitamin B2, and other light-sensitive components.
-
Oxygen-reduced packaging. Nitrogen-filled vials, oxygen scavengers, or improved container closures could support stability claims.
-
Dose-specific presentations. Premature-infant, low-birth-weight, and pediatric weight-band presentations could reduce bedside manipulation and dosing error.
-
Ready-to-use or pre-diluted formats. A validated infusion-ready product could offer operational advantages over a vial requiring pharmacy admixture.
-
Compatibility-enhanced formulations. A product with improved stability in defined amino acid, dextrose, or lipid-containing nutrition solutions could support method-of-use claims.
Patent strength would depend on unexpected stability results, narrow technical parameters, reproducible manufacturing, and differentiation from longstanding multivitamin injection formulations.
What commercial opportunities exist for M.V.I. Pediatric?
The most attractive opportunities are operational rather than purely chemical.
Ready-to-use pediatric presentations
Hospitals may value a product that reduces pharmacy preparation, transfer steps, and dosing calculations. Potential formats include:
- Unit-dose vials by weight band.
- Pre-diluted syringes for pharmacy-controlled use.
- Small-volume infusion bags.
- Dual-chamber systems separating incompatible components until administration.
- Barcoded, electronically trackable doses.
These presentations would require careful evaluation of extractables, leachables, adsorption, syringe compatibility, and in-use stability.
Supply-chain and shortage resilience
Parenteral nutrition products are vulnerable to manufacturing interruptions because sterile production capacity is concentrated. A reliable secondary supplier could compete through:
- Dual-source raw materials.
- Multiple qualified polysorbate suppliers.
- Regional fill-finish capacity.
- Larger safety-stock commitments.
- Contract manufacturing arrangements.
- Hospital group purchasing agreements.
Supply assurance can be more commercially valuable than a modest unit-price reduction when hospitals face pediatric injectable shortages.
Improved stability
A product with longer shelf life, better post-dilution stability, or improved resistance to light and oxygen could reduce wastage. The economic proposition is strongest when the product is used in low-volume pediatric settings where opened or compounded doses may be discarded.
Geographic expansion
The U.S. formulation may not match all international pediatric nutrition standards. Regional opportunities include:
- Country-specific vitamin concentrations.
- Packaging adapted to local pharmacy workflows.
- Preservative-free formats for neonatal intensive-care units.
- Smaller vial sizes for low-volume markets.
- Products aligned with local parenteral nutrition compounding practices.
Registration strategy would vary by jurisdiction. The U.S. pathway may involve an ANDA or 505(b)(2), while other markets may classify the product as a medicinal product, nutrition additive, or hospital injectable depending on local rules.
Which companies are challenging M.V.I. Pediatric?
Competition is likely to come from three groups:
- Established manufacturers of pediatric multivitamin injections.
- Generic injectable manufacturers with sterile fill-finish capacity.
- Compounding pharmacies and hospital-based pharmacy services that prepare parenteral nutrition admixtures.
Direct competition also comes from alternative vitamin products used in parenteral nutrition, including adult multivitamin injections adjusted for pediatric dosing, though such substitution is constrained by labeling, concentration, dosing, and safety considerations.
The competitive landscape is fragmented. No single product can be assessed solely on active ingredients. Hospital purchasing decisions commonly weigh FDA status, shortage history, vial size, pharmacy workload, stability data, contracting terms, and adverse-event experience.
What litigation and settlement risks affect M.V.I. Pediatric?
No major, product-defining patent litigation or Paragraph IV settlement should be assumed for M.V.I. Pediatric without a current PACER, FDA Orange Book, and FDA approval-history review. The litigation profile is likely lower than for patented small-molecule products with significant formulation or method-of-use estates.
Potential disputes could still involve:
- Patent infringement over a redesigned solubilizer system.
- Trade-secret claims involving sterile manufacturing.
- Contract disputes with distributors or group purchasing organizations.
- Product-liability claims involving contamination or particulate matter.
- Regulatory disputes over substitution or therapeutic equivalence.
- False-marking or labeling claims concerning pediatric use.
A competitor pursuing an improved formulation should complete freedom-to-operate analysis across patents covering polysorbates, micellar systems, vitamin stabilization, packaging, and parenteral nutrition admixture methods.
How strong is the M.V.I. Pediatric patent estate?
The patent estate is likely weak for the legacy product itself and potentially stronger for a differentiated successor product.
| Asset |
Likely strength |
| Legacy vitamin combination |
Low |
| Preservative-free injectable concept |
Low to moderate |
| Polysorbate 80 solubilization |
Low unless narrowly improved |
| Stability-control technology |
Moderate if supported by unexpected results |
| Ready-to-use delivery system |
Moderate |
| Pediatric dose-band packaging |
Moderate, but vulnerable to obviousness challenges |
| Manufacturing process |
Moderate to strong if process-specific and difficult to replicate |
| Biosimilar protection |
Not applicable |
The most defensible business model is a product platform based on formulation quality, validated stability, packaging, and supply reliability. A broad patent strategy focused only on the vitamin combination would likely face substantial prior-art and obviousness challenges.
What generic launch risks exist?
A generic or follow-on launch would face several technical and regulatory risks:
- Demonstrating pharmaceutical equivalence.
- Matching the vitamin strengths and dosage form.
- Establishing sterility and container-closure integrity.
- Controlling polysorbate degradation.
- Demonstrating stability after dilution and admixture.
- Managing light-sensitive vitamins.
- Establishing compatibility with parenteral nutrition solutions.
- Avoiding particulate formation.
- Validating low-volume dose accuracy.
- Securing reliable sterile manufacturing capacity.
Commercial launch risk is also significant. Hospitals may resist switching products if the incumbent has established pharmacy protocols, electronic ordering configuration, and supply contracts.
Key Takeaways
- M.V.I. Pediatric is a preservative-free pediatric multivitamin injection used in parenteral nutrition.
- Polysorbate 80 is the key functional excipient because it supports solubilization of fat-soluble vitamins.
- The major technical risks are oxidation, peroxide formation, light degradation, particulate matter, and admixture incompatibility.
- The legacy product appears to have limited patent-based protection compared with modern specialty pharmaceuticals.
- Biosimilar risk is not applicable because M.V.I. Pediatric is not a biologic.
- Generic entry would depend more on FDA pathway, reference-product status, sterile manufacturing, and formulation equivalence than on a strong composition patent.
- The strongest commercial opportunities are ready-to-use presentations, low-waste packaging, improved stability, shortage resilience, and hospital workflow integration.
- A follow-on product could obtain meaningful IP protection through stability-enhancing excipients, oxygen and light control, novel delivery formats, and validated parenteral nutrition compatibility.
FAQs
Is polysorbate 80 safe in pediatric injectable multivitamin products?
Polysorbate 80 is an established pharmaceutical excipient, but its use in pediatric injectables requires control of concentration, degradation products, peroxide content, and total exposure. Product-specific safety depends on the formulation and patient population.
Can M.V.I. Pediatric be replaced with an adult multivitamin injection?
Substitution should not be based solely on the product name. Vitamin concentrations, pediatric dosing, vitamin K content, excipients, labeling, and compatibility with parenteral nutrition must be compared before substitution.
Could a ready-to-use M.V.I. Pediatric syringe receive patent protection?
Yes. Protection could be available for a specific syringe configuration, dose-band system, stability profile, container material, or administration method. The claims would need technical distinction from existing prefilled injectable and nutrition products.
What is the most valuable improvement for a competing pediatric multivitamin injection?
The highest-value improvement is likely a combination of longer in-use stability, reduced waste, accurate low-volume dosing, and reliable compatibility with common parenteral nutrition admixtures.
Does M.V.I. Pediatric have biosimilar competition?
No. Biosimilar competition applies to biological products. M.V.I. Pediatric is a conventional vitamin-containing injectable drug product, so follow-on competition would generally involve generic or 505(b)(2) pathways.
References
-
DailyMed. (n.d.). M.V.I. Pediatric: Multiple vitamins injection, solution. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2018). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
U.S. Food and Drug Administration. (2023). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
U.S. Food and Drug Administration. (2024). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
